Abstracts tagged "interstitial lung disease"

Abstract Number: 2066 • 2019 ACR/ARP Annual Meeting
Clinical, Serologic and Morphologic Features of Interstitial Pneumonia with Autoimmune Features (IPAF): A Single Center Experience
Michael Allen¹, Emily Press ¹, Aditi Mathur ¹, Sakshi Dua ², Maria Padilla ² and Ioannis Tassiulas ², ¹Icahn School of Medicine at Mt Sinai, New York, ²Icahn School of Medicine, New York
Background/Purpose: Interstitial lung disease (ILD) encompasses a group of disorders that are classified together based on similar clinical, radiographic and pathologic findings. ILD is highly…
Abstract Number: 2616 • 2019 ACR/ARP Annual Meeting
Forced Vital Capacity Trajectories for Systemic Sclerosis-associated Interstitial Lung Disease—Analysis from the University of Michigan Scleroderma Cohort
Mirette Habib¹, Sara Jaafar ¹, Annie Park ¹, Suiyuan Huang ¹, Wen Ye ¹, Vivek Nagaraja ¹, Eric White ¹, Kevin Flaherty ² and Dinesh Khanna ³, ¹University of Michigan, Ann Arbor, MI, ²University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor, MI, ³Department of Medicine, University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor
Background/Purpose: Interstitial Lung Disease (ILD) is the leading cause of morbidity and mortality in systemic sclerosis (SSc) patients. Forced Vital Capacity (FVC, recorded as %…
Abstract Number: 1274 • 2019 ACR/ARP Annual Meeting
New Aspects of Clinical and Immunological Characteristics in Patients with Anti-KS Antibody
Sho Sasaki¹, Akira Ishii ², Mai Sugiyama ², Yuto Izumi ², Yoko Nakagome ², Kazuki Hirano ³, Takayoshi Kurabayashi ¹, Shinichi Nogi ⁴, Noriko Sasaki ², Chiho Yamada ² and Shinji Sato ⁵, ¹Tokai Universitiy School of Medicine, Isehara, Japan, ²Tokai University School of Medicine, Isehara, Japan, ³Tokai University School of Medicine, Isehara, ⁴National Hospital Organization Sagamihara Hospital, Sagamihara, Japan, ⁵Division of Rheumatology, Department of Internal Medicine, Tokai University School of Medicine, Yokohama, Japan
Background/Purpose: Anti-KS antibody, an anti-aminoacyl tRNA synthetase (ARS) antibody, is found mainly in patients with interstitial lung disease (ILD) accompanied by polymyositis/dermatomyositis (PM/DM). Although anti-KS…
Abstract Number: 2135 • 2019 ACR/ARP Annual Meeting
Therapeutic Strategies and Survival in Patients with Interstitial Pneumonia with Autoimmune Features
Marco Sebastiani¹, Giulia Cassone ², Caterina Vacchi ¹, Lisa De Pasquale ¹, Stefania Cerri ³, Giovanni Della Casa ⁴, Carlo Salvarani ¹ and Andreina Manfredi ¹, ¹Rheumatology Unit, University of Modena and Reggio Emilia, Azienda Ospedaliero-Universitaria Policlinico di Modena, MOdena, Emilia-Romagna, Italy, ²Clinical and Experimental Medicine PhD Program, University of Modena and Reggio Emilia, Modena, Emilia-Romagna, Italy, ³Respiratory Disease Unit, University of Modena and Reggio Emilia, Azienda Ospedaliero-Universitaria Policlinico di Modena, Modena, Emilia-Romagna, Italy, ⁴Radiology Unit, University of Modena and Reggio Emilia, Azienda Ospedaliero-Universitaria Policlinico di Modena, Modena, Emilia-Romagna, Italy
Background/Purpose: Recently the term “interstitial pneumonia with autoimmune features” (IPAF) has been proposed to identify patients with interstitial lung disease and autoimmune characteristics, not fulfilling…
Abstract Number: 1286 • 2019 ACR/ARP Annual Meeting
Patients with Anti-tRNA Synthetase Syndrome Are More Likely to Present to Pulmonary Clinic and Have a Higher Prevalence and Severity of Lung Disease Than Patients with Other Types of Myositis or Systemic Sclerosis
Bret Sohn¹, Erin Wilfong ¹ and Leslie Crofford ¹, ¹Vanderbilt University, Nashville
Background/Purpose: Interstitial lung disease (ILD) is a significant cause of morbidity and mortality in idiopathic inflammatory myopathies (IIM) as well as systemic sclerosis (SSc). The…
Abstract Number: 2141 • 2019 ACR/ARP Annual Meeting
Rituximab Therapy for Interstitial Pneumonia with Autoimmune Features (IPAF): A Case Series of Nineteen Patients
Kristin D'Silva¹, Marcy Bolster ¹, Flavia Castelino ², Amita Sharma ¹, Brent Little ¹, Sydney Montesi ¹ and Hyon K. Choi ¹, ¹Massachusetts General Hospital, Boston, MA, ²Harvard University, Boston, MA
Background/Purpose: Interstitial lung disease (ILD) is a major cause of morbidity and mortality in patients with connective tissue diseases (CTD). Approximately one-third of patients with…
Abstract Number: 525 • 2018 ACR/ARHP Annual Meeting
Low Interstitial Lung Disease Event Rate in Patients with Rheumatoid Arthritis: Pooled Post Hoc Analysis of Data from the Tofacitinib Clinical Development Program
Gustavo Citera¹, Eduardo Mysler², Hugo Madariaga³, Mario H Cardiel⁴, Oswaldo Castañeda⁵, Aryeh Fischer⁶, Pascal Richette⁷, Sandra Chartrand⁸, Jin Kyun Park⁹, Sander Strengholt¹⁰, Jose L Rivas¹¹, Amit Thorat¹², Tanya Girard¹³, Kenneth Kwok¹⁴, Lisy Wang¹⁵ and Dario Ponce de Leon¹⁶, ¹Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ²Organización Médica de Investigación, Buenos Aires, Argentina, ³Clínica del Sur, Arequipa, Peru, ⁴Centro de Investigación Clínica de Morelia, Morelia, Mexico, ⁵Clínica Anglo Americana, Lima, Peru, ⁶Department of Medicine, University of Colorado, Denver, CO, ⁷Lariboisière Hospital, Lariboisière, University of Paris 7, Paris, France, ⁸Department of Medicine, Hôpital Maisonneuve-Rosemont affiliated to Université de Montréal, Montréal, QC, Canada, ⁹Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea, Republic of (South), ¹⁰Pfizer Inc, Capelle aan den IJssel, Netherlands, ¹¹Pfizer SLU, Madrid, Spain, ¹²Pfizer Ltd, Mumbai, India, ¹³Pfizer Inc, Montréal, QC, Canada, ¹⁴Pfizer Inc, New York, NY, ¹⁵Pfizer Inc, Groton, CT, ¹⁶Pfizer Inc, Lima, Peru
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. Interstitial lung disease (ILD) is a common extra-articular manifestation of RA,1 and…
Abstract Number: 2979 • 2018 ACR/ARHP Annual Meeting
Innovative Approaches for the Assessment of Interstitial Lung Disease in Idiopathic Inflammatory Myopathies: Ultrasound Evaluation of Pleural Irregularities and Semiquantitative and Quantitative Analysis of Lung CT
Simone Barsotti^1,2, Chiara Romei³, Elisa Cioffi⁴, Claudia Roncella⁵, Elisabetta Perrone³, Alessandra Tripoli¹, Marta Mosca¹, Fabio Falaschi³ and Rossella Neri⁶, ¹Rheumatology Unit, University of Pisa, Pisa, Italy, ²Department of Medical Biotechnologies, University of Siena, Siena, Italy, ³Pisa University Hospital, II Radiology Unit, Pisa, Italy, ⁴Rheumatology Unit, Rheumatology Unit, University of Pisa, Pisa, Italy, ⁵Pisa University Hospital, I Radiology Unit, Pisa, Italy, ⁶Rheumatology Unit, University of Pisa, PISA, Italy
Background/Purpose: Interstitial Lung Disease (ILD) in patients with Idiopathic Inflammatory Myopathies (IIM) is associated to high mortality and morbidity. The study of pleural irregularities (PI)…
Abstract Number: 528 • 2018 ACR/ARHP Annual Meeting
Progression in Interstitial Lung Disease – Comparison of Rheumatoid Arthritis with Idiopathic Pulmonary Fibrosis
Shirish Dubey¹ and Felix Woodhead², ¹Rheumatology, University Hospital Coventry and Warwickshire NHS Trust, Coventry, United Kingdom, ²Respiratory Medicine, Glenfields Hospital, Leicester, United Kingdom
Background/Purpose: Rheumatoid Arthritis (RA) is a common autoimmune condition characterised by symmetrical inflammatory small joint polyarthropathy and loss of function. Systemic manifestations of RA are…
Abstract Number: 791 • 2018 ACR/ARHP Annual Meeting
Safety and Suitability of a Direct Thrombin Inhibitor, Dabigatran Etexilate, in Scleroderma-Associated Interstitial Lung Disease (SSc-ILD) Patients
Rick Silver¹, Ilia Atanelishvili², Tanjina Akter², Kelley Kajdasz³, Dulaney Wilson⁴, Paul J. Nietert⁵, J. Terrill Huggins⁶, Kristin B. Highland⁷ and Galina S. Bogatkevich², ¹Rheumatology, Medical University of SC, Charleston, SC, ²Division of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina, Charleston, SC, ³Division of Rheumatology & Immunology, Medical University of South Carolina, Charleston, SC, ⁴Public Health Sciences, Medical University of South Carolina, Charleston, SC, ⁵Public Health Science, Medical University of South Carolina, Charleston, SC, ⁶Pulmonology, Medical University of South Carolina, Charleston, SC, ⁷Rheumatology.org, Cleveland Clinic, Cleveland, OH
Background/Purpose: Studies from our laboratory and others have shown thrombin to be a fibrogenic mediator implicated in the pathogenesis of ILD, including scleroderma-associated ILD (SSc-ILD).…
Abstract Number: 800 • 2018 ACR/ARHP Annual Meeting
Assessment of Recent Evidence to Support Treatment Recommendations in Patients with SSc-ILD
Anna-Maria Hoffmann-Vold¹, Toby Maher², Edward Philpot³, Ali Ashrafzadeh⁴, Diwakar Jha⁵, Margarida Alves⁶ and Oliver Distler⁷, ¹Oslo University Hospital, Oslo, Norway, ²Royal Brompton Hospital, London, United Kingdom, ³IQVIA, Durham, NC, ⁴IQVIA, Los Angeles, CA, ⁵IQVIA, Gurugram, India, ⁶Boehringer Ingelheim International GmbH, Ingelheim, Germany, ⁷Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland
Background/Purpose: Systemic Sclerosis (SSc) is a chronic autoimmune disease characterized by fibrosis of skin and internal organs with an estimated worldwide prevalence of 110-430 cases/million.…
Abstract Number: 884 • 2018 ACR/ARHP Annual Meeting
Rheumatoid Arthritis Disease Activity Predicting Incident Clinically-Apparent Interstitial Lung Disease: A Prospective Cohort Study
Jeffrey A. Sparks¹, Tracy Doyle², Jie Huang¹, Beatrice Pan², Elaine Fletcher², Ritu Gill³, Hiroto Hatabu², Mizuki Nishino⁴, David Murphy², Taysir Mahmoud², Christine K Iannaccone⁵, Michelle Frits², Bing Lu⁶, Ivan O. Rosas⁷, Paul Dellaripa², Michael E Weinblatt⁵, Elizabeth Karlson⁶ and Nancy A. Shadick², ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Boston, MA, ³Beth-Israel Deaconess Medical Center, Boston, MA, ⁴Dana-Farber Cancer Institute, Boston, MA, ⁵Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁶Division of Rheumatology, Immunology and Allergy, Brigham & Women's Hospital, Harvard Medical School, Boston, MA, ⁷BWH - Pulmonary, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Determining modifiable risk factors for interstitial lung disease (ILD) is crucial given its substantial morbidity/mortality. Treatment to target of remission/low disease activity improves articular…
Abstract Number: 1013 • 2018 ACR/ARHP Annual Meeting
Circulating Hybrid M1/M2 Monocytes/Macrophages in Systemic Sclerosis Patients with Lung Involvement
Maurizio Cutolo¹, Amelia Chiara Trombetta², Veronica Tomatis³, Sabrina Paolino⁴, Carmen Pizzorni¹, Vanessa Smith⁵, Paola Contini⁶, Paola Montagna³, Renata Brizzolara² and Stefano Soldano³, ¹Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, San Martino Polyclinic Hospital, Genoa, Italy, Genoa, Italy, ²Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, IRCCS Polyclinic San Martino, University of Genoa, Genoa, Italy, ³Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, IRCCS Polyclinic San Martino, University of Genoa, Genova, Italy, ⁴Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, San Martino Polyclinic Hospital, Genoa, Italy, Genova, Italy, ⁵Department of Rheumatology, Ghent University Hospital, Ghent, Belgium, ⁶Division of Clinical Immunology, Department of Internal Medicine, University of Genova, IRCCS Polyclinic San Martino, Genova, Italy, Genova, Italy
Background/Purpose: Systemic sclerosis (SSc) is an autoimmune disease characterized by immune system alterations, vasculopathy and fibrosis [1]. SSc-related interstitial lung disease (ILD) represents a common…
Abstract Number: 1309 • 2018 ACR/ARHP Annual Meeting
Interstitial Pneumonia with Autoimmune Features: Is It Frequent?
John Fredy Jaramillo Gallego¹, Marina Scolnik², Joaquin Maritano Furcada³, Maria Laura Acosta Felquer⁴, Nicolas Martin Marin Zucaro¹, Luciano Fernando Lo Giudice¹ and Enrique R Soriano², ¹Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Capital Federal, Argentina, ²Rheumatology Unit, Internal Medicine Service. Hospital Italiano Buenos Aires. Argentina, Buenos Aires, Argentina, ³Pneumology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Capital Federal, Argentina, ⁴Rheumatology Unit, Internal Medicine Service,, Hospital Italiano de Buenos Aires, Capital Federal, Argentina
Background/Purpose: A particular subset of interstitial pneumonia, associated to one or more clinical and serological features, suggesting a possible underlying autoimmune disorder, has been described…
Abstract Number: 1331 • 2018 ACR/ARHP Annual Meeting
Moving from Dermatomyositis Associated with Anti-Melanoma Differentiation-Associated Gene 5 Antibody to Anti-Melanoma Differentiation-Associated Gene 5 Syndrome
Yves Allenbach¹, Yurdagul Uzunhan², Ségolène Toquet³, Gaëlle Leroux⁴, Laure Gallay⁵, Aude Rigolet⁶, Baptiste Hervier⁶, Nicolas Champtiaux⁶, Mathieu Vautier⁶, Perrine Guillaume⁶, Nicolas Limal⁷, Alain Meyer⁸, Christophe Deligny⁹, Bernard Bonnotte¹⁰, Hervé Devilliers¹¹, Sylvain Audia¹², Maxime Samson¹³, Amélie Servettaz¹⁴, Nathalie Costedoat¹⁵, David Saadoun¹⁶, elisabeth diot¹⁷, Alice Berezne¹⁸, Arsène Mékinian¹⁹, Kuberaka Mariampillai²⁰, Hilario Nunes² and Olivier Benveniste⁶, ¹Internal Medicine and Clinical Immunology, Sorbonne University - Assistance Public - Hopitaux de Paris, Pitié-Salpêtrière University Hospital, Paris, France, ²Pulmonary diseases department, Avicenne Hospital (AP-HP), Bobigny, France, ³Sorbonne Universités, UPMC Univ Paris 06, INSERM UMRS_974, CNRS FRE 3617, Center of Research in Myology., Paris, France, ⁴Internal Medicine, Pitié-Salpêtrière University Hospital, Paris, France, ⁵Internal Medicine, Université de Lyon - CHU Lyon, Lyon, France, ⁶Department of Internal Medicine and Clinical Immunology and Inflammation-Immunopathology-Biotherapy Department (I2B), Pitié-Salpêtrière University Hospital, Assistance Publique-Hôpitaux de Paris, East Paris Neuromuscular Diseases Reference Center, Paris, France, ⁷Internal Medicine, APHP - Henri Mondor Hospital, Paris, France, ⁸15Département de Rhumatologie, Centre de Référence des Maladies Auto-immunes Rares, Hôpitaux Universitaires de Strasbourg, Strasbourg, France, ⁹Zobda Quitman Hospital, Rheumatology and Internal Medicine, Fort de France, Martinique, ¹⁰Dijon, Dijon, France, ¹¹Service de Médecine Interne et Maladies Systémiques, CHU de Dijon, Dijon, France, ¹²Department of Internal Medicine and Clinical Immunology, Hôpital François Mitterrand, CHU de Dijon; INSERM, UMR1098, University of Bourgogne Franche-Comté, FHU INCREASE, Dijon, France, ¹³Dijon University Hospital, Dijon, France, ¹⁴Internal Medicine, CHU - Reims University, Reims, France, ¹⁵Internal Medicine, Paris Descartes Université - APHP, paris, France, ¹⁶Sorbonne Universités, UPMC Univ Paris 06, UMR 7211, and Inflammation-Immunopathology-Biotherapy Department (DHU i2B), F-75005, Paris, France; INSERM, UMR_S 959, F-75013, Paris, France; CNRS, FRE3632, F-75005, Paris, France; AP-HP, Groupe Hospitalier, Paris, France, ¹⁷Internal Medicine, Université Tours - CHU, Tours, France, ¹⁸Internal Medicine, CH Annecy, Annecy, France, ¹⁹Service de médecine interne. Hôpital Saint-Antoine., Paris, France, ²⁰Département de Médecine Interne et Immunologie Clinique, Centre de Référence des Maladies Neuro-Musculaires Paris Est, Assistance Publique – Hôpitaux de Paris (AP-HP), Hôpital Universitaire Pitié-Salpêtrière, Paris, France
Background/Purpose: Dermatomyositis (DM) is a heterogenous group of diseases ranging from skin limited disorders to non-specific auto-immune diseases with patients suffering from additional extra-cutaneous manifestations.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].